Skip to content
Action Kidney Cancer Logo Action Kidney Cancer Logo
  • Home
  • About us
  • Contact us
  • Help & support
  • Kidney cancer
  • Research
  • Get involved
  • Downloads
  • Home
  • About us
  • Contact us
  • Help & support
  • Kidney cancer
  • Research
  • Get involved
  • Downloads
Helpline
0800 121 8721
Email us
Donate

Surgery after targeted therapy or immunotherapy for metastatic kidney cancer

Home/Uncategorized/Surgery after targeted therapy or immunotherapy for metastatic kidney cancer

Surgery after targeted therapy or immunotherapy for metastatic kidney cancer

5 Oct 2020

Tags
checkpoint inhibitors cytoreductive nephrectomy immunotherapy neoadjuvant therapy nephrectomy renal cell carcinoma targeted therapy
  • View Larger Image
Listen to this News
Print this News

Share this Page:

FacebookTwitterLinkedInWhatsAppTumblrPinterestVkXingEmail

A recent retrospective study (looking back at the patients’ cases after treatment had occurred) has shown that patients with metastatic renal cell carcinoma (RCC) who were treated with targeted therapy, such as sunitinib or pazopanib, or immunotherapy, such as nivolumab, had better survival outcomes if went on to have surgery to remove the kidney. This is called neoadjuvant treatment.

There were 4,639 patients with metastatic RCC in the trial and who were treated with either immune checkpoint inhibitor or targeted therapy. A total of 4,202 patients were on a targeted therapy. Of these patients, 2,631 had nephrectomy while 1,571 did not. Meanwhile, 437 of the patients were on immune checkpoint inhibitors, 245 of whom had nephrectomy while 192 did not. The data came from more than 40 centres across the world.

The patients were followed for an average of 38.5 months. Patients who were treated with targeted therapy before they had their nephrectomy experienced an average overall survival of 26.5 months versus 10.3 months in those who did not have nephrectomy.

Patients who had immune checkpoint inhibitor treatment before nephrectomy had an average overall survival of 53.6 months versus 21.4 months for patients who were not on neoadjuvant immunotherapy.

However, not every patient with metastatic RCC will benefit from nephrectomy followed by targeted treatment or immunotherapy. Some studies, such a the CARMENA trial found that patients who had one risk factor (such as low haemoglobin or high calcium levels) benefited from surgery before receiving sunitinib, especially if they had only one site of disease spread.

Read more in Cure here

Listen to this News
Print this News

Share this Page:

FacebookTwitterLinkedInWhatsAppTumblrPinterestVkXingEmail

Kidney cancer news

23 Mar 2023

Savolitinib and durvalumab for metastatic papillary kidney cancer

Read More

23 Mar 2023

One Cancer Voice petition: 80,000 demand diagnosis and treatment is top priority

Read More

20 Mar 2023

Adjuvant nivolumab plus ipilimumab for localised kidney cancer

Read More

20 Mar 2023

Fat loss may result in worse outcomes for patients treated with immunotherapy for metastatic kidney cancer

Read More

16 Mar 2023

Results from a phase 3 study of 89Zr-DFO-girentuximab for PET/CT imaging of kidney cancer

Read More

16 Mar 2023

Improved health-related quality of life using a mindfulness app for kidney cancer patients

Read More

16 Mar 2023

How time of day of immunotherapy infusion affects kidney cancer outcomes

Read More

15 Mar 2023

Benefits persist for lenvatinib plus pembrolizumab in advanced kidney cancer

Read More

9 Mar 2023

TKI treatment breaks may not affect outcomes in kidney cancer

Read More

7 Mar 2023

ASCO GU 20023: Cabozantinib as a second-line treatment for patients with advanced kidney cancer

Read More

7 Mar 2023

ASCO GU 2023: A triple combination for previously untreated kidney cancer patients

Read More

6 Mar 2023

ASCO GU 2023: Treatment-free survival for advanced kidney cancer patients on nivolumab and salvage nivolumab/ipilimumab

Read More

Most used tags

renal cell carcinoma immunotherapy combination therapy checkpoint inhibitors Cancer nivolumab TKIs overall survival Opdivo sunitinib Sutent progression-free survival cabozantinib biomarkers NHS England Cabometyx ipilimumab pembrolizumab COVID-19 cancer survival axitinib VEGF inhibitors non-clear cell kidney cancer Inlyta coronavirus Yervoy risk factors Keytruda metastases adjuvant therapy biological markers papillary RCC targeted therapy everolimus Afinitor ASCO cancer outcomes first-line treatment NICE partial nephrectomy

Archives

  • 2023: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
  • 2022: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
  • 2021: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
  • 2020: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
  • 2019: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
  • 2018: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
  • 2017: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
  • 2016: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
  • About kidney cancer
  • Kidney cancer news
  • Kidney cancer treatments
  • Newsletter
  • Glossary
  • Useful links

Address

Action Kidney Cancer

11th Floor
3 Piccadilly Place
Manchester M1 3BN

Helpline

0800 121 8721
Email Us

About Action Kidney Cancer

We are the UK’s largest and most active patient-led kidney cancer charity. Whether you are a patient, survivor or someone you know has been diagnosed with kidney cancer, you have come to the right place to find support and information, and to be part of a caring and knowledgeable community of people: We are here to help you.
Registered charity in England, Wales (1164238), and Scotland (SC051330).
© Copyright Action Kidney Cancer 2021

Links

Home

About us

Donate

Contact us

Our partners

Branding by Kingswood Marketing

Policies

Website Policies

Complaints Policy

Equal Opportunities Policy

Information Governance Policy

Social Media Policy

Follow

Web Design by Douglass Digital

Helpline: 0800 121 8721

support@actionkidneycancer.org

Go to Top